Sleep Cycle

Sleep Cycle reported net revenue of just under SEK 50 million in the second quarter, a decline of about 20% year‑on‑year. Reported EBIT was a loss of SEK 7.5 million, while adjusted EBIT was positive at SEK 3.4 million. Paying subscribers fell 24.3% to 665,000, while B2B revenue rose by around 30% and now accounts for about 15% of total revenue. The stock fell 2.4% in early trading to $24.35; management plans to pursue FDA approval for the sleep apnea program in 2027 but will need a larger study to do so. » Plus sur de.investing.com

Sleep Cycle recorded a net revenue decline of 6.6% to CHF 62 million in the third quarter of 2025 and a 9% drop in paying subscribers to 832,000. Partnership revenues rose 55%, EBIT was CHF 17 million (margin 27.3%) and cash liquidity stood at CHF 114 million. The figures missed expectations (revenue forecast CHF 63.5 million) and prompted a pre-market share drop of around 11% to CHF 26.5; the stock is approaching its 52-week low. » Plus sur de.investing.com

Sleep Cycle AB reported declining paying subscribers and a slight revenue decline in Q2 2025, but maintained a robust adjusted EBIT margin of 28.4% and SEK 18 million in EBIT. Partnership revenues rose 68% and account for 9% of revenue, while the company is pursuing a strategic expansion into the sleep apnea market with clinical trials and a B2B platform approach. The stock fell about 6.6% after the results, reflecting investor concerns about the near-term recovery of subscriber and revenue trends. » Plus sur de.investing.com